Cancer Research Meeting Calendar Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bratland, A.
Right arrow Articles by Ree, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bratland, A.
Right arrow Articles by Ree, A. H.
[Cancer Research 60, 5578-5583, October 1, 2000]
© 2000 American Association for Cancer Research

Tumor Biology

Expression of a Novel Factor, com1, Is Regulated by 1,25-Dihydroxyvitamin D3 in Breast Cancer Cells1

Åse Bratland, Karianne Risberg, Gunhild M. Mælandsmo, Kristine Bjerve Gützkow, Øyvind E. Olsen, Amir Moghaddam, Meng-yu Wang, Christina Mørk Hansen, Heidi Kiil Blomhoff, Jens P. Berg, Øystein Fodstad and Anne Hansen Ree2

Departments of Tumor Biology [Å. B., K. R., G. M. M., Ø. E. O., A. M., M-y. W., Ø. F., A. H. R.] and Oncology [A. H. R.], The Norwegian Radium Hospital, 0310 Oslo, Norway; University of Oslo, Institute of Medical Biochemistry, 0317 Oslo, Norway [K. B. G., H. K. B.]; Aker University Hospital, Hormone Laboratory, 0514 Oslo, Norway [J. P. B.]; and Leo Pharmaceutical Products, 2750 Ballerup, Denmark [C. M. H.]


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Tumor cells and their surrounding microenvironment produce a variety of factors that promote tumor growth and metastasis. We recently identified a nuclear factor, termed com1, that is up-regulated in human breast carcinoma cells on formation of experimental metastatic tumors and is assumed to act as a growth-promoting factor in breast cancer. 1,25-Dihydroxyvitamin D3 [1,25(OH)2D3] is a potent inhibitor of growth in breast cancer both in vitro and in vivo. We compared the growth-regulatory mechanisms of nontumorigenic and estrogen-dependent MCF-7 cells with those of the tumorigenic and tamoxifen-resistant subline MCF7/LCC2 in the presence of 1,25(OH)2D3. Proliferation of MCF7/LCC2 cells, which revealed constitutive com1 expression, was inhibited by 1,25(OH)2D3 (10-7 M). This was strongly associated with cell cycle arrest in G1 phase, consistent with accumulation of the hypophosphorylated form of the retinoblastoma protein as well as the induction of the cyclin-dependent kinase inhibitor p21. These cell cycle events were preceded by a transient up-regulation (5–8-fold) of com1 mRNA. Furthermore, clonal growth of the MCF7/LCC2 cells was also inhibited by 1,25(OH)2D3 (10-7 M), and when the com1-negative MCF-7 cells were stably transfected with com1, the resulting MCF7/com1 cells showed a significant decrease in colony formation. These results seem to indicate that rather than promoting growth, com1 may participate in the regulatory pathway involved in cellular growth inhibition when recruited by inhibitory signals.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
After malignant transformation, tumor cells and their surrounding stroma produce a variety of factors within the tumor cell environment to promote tumor growth and metastasis (1) . Moreover, current evidence suggests that metastasis formation is primarily the result of the ability of disseminated tumor cells to initiate and continue growth in the target organ (2 , 3) . We recently reported a novel approach, comparing the phenotypes of human breast carcinoma cells acquired from an early step in clinical tumor progression and the cell population isolated from experimental metastases formed by these tumor cells, to identify properties that might prevail in the metastatic cells. A factor termed com1 was identified as up-regulated in the metastatic cell population. com1 presumably represents a helix-turn-helix-type DNA-binding protein and may participate in the response of breast carcinoma cells to growth conditions offered by the target organ on formation of distant metastases (4) .

In addition to its role in the calcium metabolism, vitamin D also promotes tissue differentiation and inhibits cellular proliferation. Several reports have described antiproliferative effects of vitamin D in breast cancer cells in culture (5, 6, 7) , and it has been suggested that noncalcemic vitamin D analogues may have a clinical potential in the treatment of breast cancer (8 , 9) . Furthermore, epidemiological studies have shown an inverse correlation between average annual sunlight exposure and the incidence of breast cancer, suggesting an association between endogenous vitamin D production and breast carcinogenesis (10 , 11) .

The aim of the present study was to examine whether cellular com1 expression may be associated with vitamin D-dependent growth regulation of breast cancer cells. We used the human cell line MCF-7 and its derivative subline MCF7/LCC2, which reflect phenotypes of the carcinoma cells observed during clinical progression of breast cancer. The com1-negative MCF-7 cells (4) are highly responsive to estrogens but poorly tumorigenic in animal models (12) . In contrast, the estrogen-independent MCF7/LCC2 cells, which are also tamoxifen resistant and possess a tumorigenic phenotype (12 , 13) , show constitutive com1 expression (4) . The active metabolite of vitamin D, 1,25(OH)2D3,3 promoted growth inhibition of the MCF7/LCC2 cells mediated by induction of the cdk inhibitor p21 and concomitant hypophosphorylation of pRB. These events, ultimately leading to cell cycle arrest in the G1 phase, were preceded by a transient induction of cellular com1 expression. Because expression of com1 mRNA was also inversely correlated to clonal growth of MCF-7 cell lines, we postulate that com1 may participate in the regulatory pathway involved in cellular growth control when recruited by inhibitory signals.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Cultures.
The MCF-7 human breast cancer cells were routinely grown in MEM containing phenol red (Life Technologies, Inc., Rockville, MD) supplemented with 5% FCS (Life Technologies, Inc.), insulin (5.0 µM; Sigma, St. Louis, MO), and glutamine (2.0 mM; Life Technologies, Inc.). The subline MCF7/LCC2 was routinely grown in MEM without phenol red (Life Technologies, Inc.) supplemented with insulin and glutamine as described above, in addition to 5% steroid-depleted FCS. The serum was stripped of endogenous steroids by treatment with charcoal as described previously (14) . The MCF7/com1 and MCF7/pMAM cells were grown in the same medium as MCF-7 supplemented with Geneticin (G418; Sigma). Cell cultures were kept at 37°C in a humidified 5% CO2 atmosphere and refed every 3–4 days. Twenty-four h before the start of all experiments, media were exchanged, and cells were further incubated in the absence of insulin (defined as experimental media). All experiments were conducted on cells in exponential growth phase.

Cellular Proliferation.
The MCF-7 and MCF7/LCC2 cells were seeded in experimental media on culture dishes (6-cm in diameter; 2.5 x 105 cells/dish). After 24 h (at the start of the experimental period), medium was changed, and the cells were grown in the absence or presence of 1,25(OH)2D3 (10-7 M; a generous gift from Dr. L. Binderup; Leo Pharmaceutical Products, Ballerup, Denmark) for up to an additional 96 h. For both cell lines, the seeding of this particular cell number resulted in near confluent growth at the end of the incubation period. At time points 0, 24, 48, 72, and 96 h, respectively, control and treated cells were harvested by trypsination, and trypan blue-excluding cells were counted using a Bürker’s counting chamber. All cell number determinations were performed in triplicate, and the internal variation in counts was <5%. Three separate sets of experiments with three parallel samples for each condition were performed.

Flow Cytometry Analysis.
Cells were harvested, fixed in 1% paraformaldehyde, and subsequently resuspended in 100% methanol for storage at -20°C. The staining procedure was performed for each sample in a 50-µl solution consisting of 5 units of biotinylated terminal transferase (Boehringer Mannheim, Mannheim, Germany), 0.5 nmol of biotin-16-dUTP (Boehringer Mannheim), 1.5 mM CoCl2, and 0.1 mM DTT. After incubation for 30 min at 37°C, cells were washed with PBS and incubated for another 30 min in 50 µl of streptavidin-conjugated FITC (Amersham Pharmacia Biotech, Uppsala, Sweden) diluted 1:50 in PBS with 0.1% Triton X-100. Cell pellets were finally resuspended in 500 µl of PBS containing 0.1% Triton X-100, 100 µg/ml RNase A, and 5 µg/ml propidium iodide. Stained cells were analyzed in a FACStar+ laser flow cytometer with excitation at 488 nm, and DNA content (integrated propidium iodide fluorescence, collected using linear amplification) versus replicative cell fractions (FITC fluorescence intensity, collected using logarithmic amplification) was measured.

Western Blot Analysis.
Cells were harvested and homogenized in ice-cold lysis buffer [250 mM NaCl, 2 mM EDTA, 0.1% NP40, 1 mM DTT, 1 mM NaF, 1 mM orthovanadate, 60 mM ß-glycerophosphate, 50 µg/ml phenylmethylsulfonyl fluoride, and 2 µg/ml each of aprotinin and leupeptin (pH 7.2); Ref. 15 )]. Aliquots of 30 µg of total protein were separated on 7.5% (for detection of pRB) or 12% (for detection of the other proteins) SDS-PAGE and transferred to nitrocellulose membranes (Amersham Pharmacia Biotech) by standard methods. The membranes were blocked in TBS-T containing 5% nonfat dry milk for 1 h at room temperature and subsequently incubated with 1 µg/ml dilutions of mouse antihuman antibodies in TBS-T for 2 h at room temperature. The antibodies were anti-pRB [G3–254; purchased from PharMingen (San Diego, CA)] and anti-p21 (C-19), anti-p27 (C-19), anti-cdk4 (C-22), and anti-cyclin D1 C-20 [all obtained from Santa Cruz Biotechnology (Santa Cruz, CA)]. After four washes with TBS-T, the membranes were incubated with a 1:6000 dilution of horseradish peroxidase-linked secondary antibody (Bio-Rad, Hercules, CA), and immunoreactive proteins were visualized with the enhanced chemiluminescence detection system (Amersham Pharmacia Biotech).

Generation of Stable MCF7/com1 and MCF7/pMAM Transfectants.
A PCR-generated DNA fragment containing the complete coding region of com1 (4) was ligated in-frame into the EcoRI site behind the Dex-inducible promoter of the mammalian expression vector pMAMneo (Clontech, Hampshire, United Kingdom). This construct was transfected into MCF-7 cells by electroporation. Individual stable transfectants were selected in media containing 2 mg/ml G418 and maintained in media containing 500 µg/ml G418. Control MCF7/pMAM transfectants were generated correspondingly, but with the use of an empty pMAMneo vector instead. The com1 transcript was found to be inducible by Dex in the MCF7/com1 cells.

Northern Blot Analysis.
Total RNA was extracted and analyzed by standard Northern blotting techniques. Samples of 10 µg of RNA were resolved by gel electrophoresis before transfer onto Hybond-N+ membranes (Amersham Pharmacia Biotech). The cDNA probes were labeled with [{alpha}-32P]dCTP (Amersham Pharmacia Biotech) by using the random priming technique, and standard Church hybridization conditions were used. To evaluate the amounts of RNA loaded, the filters were rehybridized to a kinase-labeled oligonucleotide probe complementary to nucleotides 287–305 of human 18S rRNA. Finally, the autoradiographs were subjected to densitometric measurements in a Molecular Dynamics 300A laser densitometer, and the mRNA expression levels relative to 18S rRNA were calculated.

Clonal Growth Assay.
Soft agar cultures were performed in tubes by adding 0.2 ml of nude rat blood diluted 1:8 in experimental media, 0.6 ml of 0.5% agar (Difco Laboratories, Ltd., Surrey, United Kingdom) in experimental media, and a 0.2-ml suspension of cells grown for 24 h in experimental media (500 cells/culture sample). The cultures contained a final concentration of 5% steroid-depleted FCS for the MCF7/LCC2 cells or 15% FCS for the MCF-7, MCF7/pMAM, and MCF7/com1 cells. The tubes were incubated at 37°C in 5% CO2, 5% O2, and 90% N2. Experimental media (1 ml) with the proper concentrations of 1,25(OH)2D3, Dex, or ethanol vehicle were added on days 7 and 14. Colonies of >2 mm were scored after 21 days of incubation using a Nikon stereomicroscope. Experiments with six to nine parallel samples for each condition were performed.

Statistics.
The statistical analyses were performed using the SigmaStat software program (Jandel, Erkrath, Germany) with a significance level of P < 0.05.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Regulation of Cellular Proliferation and the Cell Cycle by 1,25(OH)2D3.
The MCF-7 and MCF7/LCC2 cells were cultured in the absence or presence of 1,25(OH)2D3 (10-7 M), and growth was measured after 0–96 h of incubation (Fig. 1)Citation . Both cell lines revealed an exponential growth pattern of untreated cells (a 6–8-fold increase in cell number after 96 h), whereas a striking difference was observed between the cell lines in the presence of 1,25(OH)2D3. The MCF-7 cells still showed exponential growth, although the growth rate was significantly reduced after 72–96 h of treatment. In the MCF7/LCC2 cells, the exponential growth pattern was abolished in the presence of 1,25(OH)2D3. However, a significant inhibitory effect compared with the control situation was not observed before 72 h.



View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Time-dependent effects of 1,25(OH)2D3 on cellular proliferation. The MCF-7 and MCF7/LCC2 cells were incubated in the absence ({circ}) or presence (•) of 1,25(OH)2D3 (10-7 M) for 0–96 h, and in vitro growth was assessed. The values are representative of three independent experiments and are presented as the mean ± SD of triplicate determinations of each condition. *, values of 1,25(OH)2D3-treated cells that were significantly different from the values of controls from the corresponding incubation time (P < 0.0001, Student-Newman-Keuls’ test). In both cell lines, values obtained from both control and 1,25(OH)2D3-treated cells incubated for 48–96 h were significantly higher than the values of the control cells at 0 h (P < 0.05, Student-Newman-Keuls’ test).

 
To characterize the mechanism of growth inhibition by 1,25(OH)2D3, the cells were cultured in the absence or presence of 1,25(OH)2D3 (10-7 M) for 48 h. First, cell cycle profiles were analyzed by flow cytometry (Fig. 2)Citation . The cell cycle distribution showed 1,25(OH)2D3-dependent accumulation of MCF7/LCC2 cells in the G1 phase. Signals corresponding to apoptotic cells were almost absent, as shown by gates R2 (displaying apoptotic cell fractions) of the histograms. Subsequently, the phosphorylation status of pRB was examined (Fig. 3)Citation . Consistent with the flow cytometry data, an accumulation of the hypophosphorylated form of pRB was observed in the 1,25(OH)2D3-treated MCF7/LCC2 cells.



View larger version (33K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. 1,25(OH)2D3-dependent regulation of cell cycle profiles. The MCF-7 and MCF7/LCC2 cells were incubated in the absence (-) or presence (+) of 1,25(OH)2D3 (10-7 M) for 48 h, and cell cycle parameters were analyzed by flow cytometry. The histograms display DNA content (integrated propidium iodide fluorescence; F-32) versus replicative cell fractions (FITC fluorescence; FL1), and the profiles are representative of three independent experiments. Cells in G1 phase, S phase, and G2-M phase are found in channel numbers ~200, 250–350, and ~400 along the F-32 axes, respectively. Gates R2 display apoptotic cell fractions (by terminal transferase staining).

 


View larger version (28K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. 1,25(OH)2D3-dependent regulation of phosphorylation pRB. The MCF-7 and MCF7/LCC2 cells were incubated in the absence (-) and presence (+) of 1,25(OH)2D3 (10-7 M) for 48 h, and expression of hyperphosphorylated (hyper-pRB) and hypophosphorylated (hypo-pRB) forms of pRB was analyzed by Western blot hybridization. The autoradiographs are representative of two independent experiments.

 
Among the factors involved in regulation of the cell cycle, p21 has been shown to be a primary target for transcriptional regulation by vitamin D (9 , 16) . Hence, mRNA expression of p21 and other factors involved in regulation of the G1 phase was analyzed (Fig. 4a)Citation . Both cell lines showed constitutive mRNA expression of the cdk inhibitors p21 and p27, as well as of cdk4, cyclin D1, and p53, all of which represent factors involved in G1 cell cycle control (17) . Of these, only p21 was significantly up-regulated (>2-fold; p21 mRNA: 18S rRNA ratio) by 1,25(OH)2D3, but again, this was observed solely in the MCF7/LCC2 cells. However, it has also been reported that vitamin D-dependent control of the involved cell cycle factors is generally exerted at the level of the proteins (9) , particularly regulated degradation of cyclin D1 (18) . Hence, protein expression of the key factors was determined (Fig. 4b)Citation . Yet again, both cell lines showed constitutive expression of p21, p27, cdk4, and cyclin D1, but only p21 seemed to be a target for 1,25(OH)2D3-dependent regulation. The induction of p21 at the protein level in the MCF7/LCC2 cells was closely identical with the corresponding regulation of its mRNA.



View larger version (34K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. 1,25(OH)2D3-dependent expression of factors involved in the G1 phase of the cell cycle. The MCF-7 and MCF7/LCC2 cells were incubated in the absence (-) and presence (+) of 1,25(OH)2D3 (10-7 M) for 48 h. a, expression of mRNAs for p21, p27, cdk4, cyclin D1, and p53 was analyzed by Northern blot hybridization. The 18S rRNA was estimated as an assay control. The autoradiographs are representative of three independent experiments. b, expression of p21, p27, cdk4, and cyclin D1 was analyzed by Western blot hybridization. The autoradiographs are representative of two independent experiments.

 
Finally, neither baseline nor 1,25(OH)2D3-dependent expression of mRNAs for cdk2, the cdk4 inhibitors p15 and p16 (17) , or the tumor suppressor BRCA1, which may trans-activate the 5'-flanking region of the p21 gene (19) , was observed in any cell line (data not shown).

Effects of Steroid Hormones and Steroid-like Factors on com1 mRNA Expression.
To examine whether cellular com1 expression may be associated with the observed growth inhibition, com1 mRNA was measured in the MCF-7 and MCF7/LCC2 cells after treatment with 1,25(OH)2D3 (10-7 M) for 24 h. For comparison, the cells were also incubated in the presence of 10-7 M each of E2, Dex, or RA because these steroids are also known to regulate breast cancer growth (Fig. 5)Citation . In the com1-negative MCF-7 cells, expression of com1 mRNA was below the level of detection, irrespective of the mode of treatment. Whereas E2, Dex, or RA did not significantly alter the baseline expression of com1 mRNA in the MCF7/LCC2 cells, a surprising up-regulation of com1 mRNA was observed in the presence of 1,25(OH)2D3.



View larger version (44K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Effects of steroid hormones and steroid-like factors on com1 mRNA expression. The MCF-7 and MCF7/LCC2 cells were treated for 24 h with 10-7 M each of E2, 1,25(OH)2D3, Dex, or RA, as indicated, and the levels of com1 mRNA were analyzed. Control cells were kept in 0.1% ethanol for 24 h. The autoradiographs are representative of three independent experiments.

 
Regulation of com1 mRNA Expression by 1,25(OH)2D3.
Based on the previous experiments, the MCF7/LCC2 cells were incubated in the presence of 1,25(OH)2D3 (10-7 M) for 0–48 h, and com1 mRNA was analyzed (Fig. 6)Citation . The expression of com1 mRNA showed a biphasic induction (5–8-fold) with a peak level at 24 h followed by a gradual decline after 36–48 h of 1,25(OH)2D3 treatment. Hence, the kinetics of this induction was much faster than the cell cycle events leading to the growth arrest of the MCF7/LCC2 cells. After 36–48 h of incubation, an up-regulation of com1 mRNA was also observed in the control cells.



View larger version (48K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 6. Time-dependent regulation of com1 mRNA expression by 1,25(OH)2D3. a, Northern blot analyses were performed on RNA recovered from control cells (-) or cells treated with 10-7 M 1,25(OH)2D3 (+) for the indicated time periods (0–48 h). The autoradiographs of com1 mRNA and 18S rRNA are representative of three independent experiments. b, densitometric reading values of the com1 mRNA/18S rRNA signals from the control ({circ}) and 1,25(OH)2D3-treated (•) cells in a. Values are plotted relative to the time 0 value.

 
Clonal Growth of MCF-7 Cell Lines.
The 1,25(OH)2D3-dependent regulation of com1 seemed to be an early regulatory event in growth inhibition of the MCF7/LCC2 cells. The question of whether com1 might also be involved in long-term growth control was assessed by a colony formation assay. First, MCF7/LCC2 cells dispersed in soft agar were incubated with increasing concentrations of 1,25(OH)2D3 (10-11 to 10-7 M; Fig. 7Citation ). Whereas the lower concentrations (10-11 to 10-9 M) were associated with significant stimulatory effects, half-maximal inhibition of clonal growth was observed at a concentration of ~10-8 M, and complete suppression of colony formation was obtained at 10-7 M.



View larger version (24K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 7. 1,25(OH)2D3-dependent regulation of clonal growth of MCF7/LCC2 cells. Five hundred cells were seeded in 1 ml of soft agar medium containing 5% steroid-depleted FCS, and the number of colonies was assessed after incubation in the absence (0 M) or presence of increasing concentrations (10-11 to 10-7 M) of 1,25(OH)2D3 for 21 days. The values are representative of three independent experiments and are presented as the median and 75% confidence intervals of values obtained from nine parallel incubations for each condition. *, values that were significantly different from the values of the control group (P < 0.0001, Student-Newman-Keuls’ test).

 
To strengthen the association between com1 expression and clonal growth of the MCF-7 cell lines, the com1-negative MCF-7 cells were stably transfected with a Dex-inducible com1 construct, and the resulting MCF7/com1 cells were compared with the wild-type parental cells and MCF7/pMAM control transfectants with regard to colony formation in soft agar (Fig. 8)Citation . Dex at concentrations of 10-7 to 10-5 M caused inhibition (30–35%) of clonal growth of both the MCF-7 and MCF7/pMAM cells (Fig. 8b)Citation . In contrast, clonal growth of the MCF-7/com1 cells was inhibited by 65–75% in the presence of Dex (Fig. 8b)Citation . Importantly, the transfected cells expressing Dex-inducible com1 mRNA (Fig. 8a)Citation also revealed significant down-regulation (50–60%) of colony formation when compared with the MCF-7 and MCF7/pMAM cells treated with Dex (Fig. 8b)Citation .



View larger version (46K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 8. com1 transfection of MCF-7 cells and effect on clonal growth. a, the MCF7/com1 cells represent MCF-7 cells stably transfected with a com1 construct. The Northern blot illustrates the induction of com1 mRNA expression in the MCF7/com1 cells by increasing concentrations (10-7 to 10-5 M) of Dex for 48 h, with the wild-type MCF-7 cells and MCF7/pMAM control transfectants used as negative controls. The autoradiographs of com1 mRNA and 18S rRNA are representative of three independent experiments. b, clonal growth of the MCF7/com1 cells compared with the MCF-7 and MCF7/pMAM cells, as analyzed by a soft agar assay. Five hundred cells were seeded in 1 ml of soft agar medium containing 15% FCS, and the number of colonies was assessed after incubation in the absence (0 M) or presence of increasing concentrations (10-7 to 10-5 M) of Dex for 21 days. The values are presented as the mean ± SD of values obtained from six parallel incubations for each condition. *, values that were significantly different from the values of the MCF-7 wild-type and control MCF7/pMAM groups (P < 0.001, Student-Newman-Keuls’ test). The MCF7/pMAM values were statistically equal to the corresponding MCF-7 values, but within all three cell lines, values obtained from Dex-treated cells were significantly lower than the control values (P < 0.001, Student-Newman-Keuls’ test).

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In the present study we demonstrated that 1,25(OH)2D3 inhibited in vitro growth of the com1-positive MCF7/LCC2 cells. This was associated with up-regulation of p21 and the subsequent accumulation of the hypophosphorylated form of pRB, ultimately leading to cell cycle arrest in G1 phase. Moreover, a 1,25(OH)2D3-dependent induction in com1 mRNA expression was closely associated with the growth-inhibitory effect, suggesting that com1 may participate in the regulatory pathway involved in cellular growth inhibition.

Vitamin D is a recognized inhibitor of cell proliferation in model systems of several human malignancies (5, 6, 7 , 9 , 20, 21, 22, 23, 24) . The cell cycle events observed in the 1,25(OH)2D3-treated MCF7/LCC2 cells are consistent with the identification of a vitamin D response element in the 5'-flanking region of the p21 gene and with the notion that the VDR trans-activates p21 independently of the tumor suppressor p53 (16) .

We recently identified com1 as a nuclear factor that may mediate the proliferative response of breast carcinoma cells on establishment in secondary organs during experimental metastasis formation (4) . Based on these results, it is rather intriguing that treatment of the MCF7/LCC2 cells with 1,25(OH)2D3 caused an up-regulation of the level of com1 mRNA. This vitamin D-dependent effect seemed to be rather specific because the other steroid hormones and steroid-like factors tested (E2, Dex, and RA), all of which are known to modulate experimental or clinical progression of breast cancer, did not alter the expression of com1 mRNA.

The VDR is a ligand-operated transcription factor, which principally acts in a heterodimer complex that stimulates target gene transcription via vitamin D response elements (25) . Thus far, only a few primary vitamin D-responding genes have been identified (9) , and p21 is one of these (16) . The possibility that the com1 gene is transcriptionally activated by the VDR is particularly appealing but still unproven and demands comprehensive experiments on the still uncharacterized 5'-flanking region of the human com1 gene.

The facts that the kinetics of the transient 1,25(OH)2D3-dependent induction of com1 mRNA was much faster than the cell cycle events leading to growth arrest of the MCF7/LCC2 cells and that the growth rate of the com1-negative MCF-7 cells was also inhibited by 1,25(OH)2D3 argue against a direct involvement of com1 in cell cycle regulation. Our preliminary observation that the level of p21 mRNA in the MCF7/com1 cell line does not apparently differ from that in the MCF-7 wild-type or MCF7/pMAM control cells (data not shown) is another argument. The increase in the level of com1 mRNA in control MCF7/LCC2 cells after 36–48 h of incubation, which is followed by a shift toward hypophosphorylated pRB and G1 arrest after 96 h (data not shown), illustrates the same concept. This growth retardation of the control cells is presumably due to consumption and a subsequent lack of nutrients in the medium exchanged no later than at time 0. Nevertheless, the striking inverse correlation between com1 mRNA expression and colony formation in the MCF7/com1 cells supports the notion of some growth-regulatory effect of com1, although the suppression of clonal growth of the com1-transfected cell line was incomplete.

The gene sequence for com1 is earlier described as the rat cDNA analogue p8 by Mallo et al. (26) . The authors found that pancreatic expression of p8 was strongly enhanced after stimuli that induce apoptosis (26) . The kinetics of these p8 mRNA responses seems closely comparable with our observations on 1,25(OH)2D3-dependent regulation of com1 mRNA. Several reports have shown that 1,25(OH)2D3 and vitamin D analogues activate apoptotic death pathways in breast cancer cells (27, 28, 29, 30) . In contrast to this, our flow cytometry analysis revealed hardly any signals corresponding to apoptotic cells. However, we did not specifically examine other apoptotic features of the 1,25(OH)2D3-treated MCF7/LCC2 cells.

Mallo et al. (26) also demonstrated high levels of p8 mRNA expression in developing and regenerating rat pancreas and liver. The authors also showed increased activity in cellular growth assays, but no alterations were seen in response to apoptotic stimuli on cellular overexpression of p8 by transfection (26 , 31) . Our own initial identification of human com1 was from actively proliferating metastatic tumors (4) , representing biological entities in which the relative fraction of apoptotic cells is low (32) . We have also found that the expression levels of com1 mRNA in human breast tumors are consistently and significantly higher than those in the adjacent normal breast tissue (33) . Notably, the com1 gene has a localization within chromosome 16 at position p11.2 (31) , a chromosomal region occasionally amplified in primary breast tumors (34, 35, 36) , which supports the assumption that com1 may function as a growth-promoting factor in the development of malignant breast tumors.

It is conceivable to assume that com1/p8 plays some regulatory role in cellular growth, although the previously published (4 , 26 , 31 , 33) and present data are apparently conflicting. We speculate that com1 may mediate growth stimulation as well as inhibition by being recruited by preferentially stimulatory or inhibitory signals and perhaps by acting with different nuclear partners in a cell- or tissue-specific manner. To analyze the effect of com1 alone, we established the MCF7/com1 transfectants from the com1-negative MCF-7 cell line. Although we used a construct demanding the use of a potent corticosteroid analogue with an inhibitory effect on cellular proliferation, the induced MCF7/com1 cells revealed significant inhibition of colony formation in the soft agar assay compared with both the wild-type MCF-7 cells and MCF7/pMAM control transfectants treated with Dex.

In conclusion, the present study demonstrated that 1,25(OH)2D3 exerts highly regulated antiproliferative control of the com1-positive MCF7/LCC2 cell line. The regulatory mechanism was confirmed to involve the cell cycle inhibitor p21, and a striking association with a preceding com1 mRNA induction was observed. The MCF7/com1 cell line established from the com1-negative MCF-7 cells seemed to mimic 1,25(OH)2D3-treated MCF7/LCC2 cells in a clonal growth assay. These results apparently indicate that rather than promoting growth, com1 may mediate growth inhibition of MCF-7 cell lines.


   ACKNOWLEDGMENTS
 
We thank Dr. N. Brünner (Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark) for the gift of the MCF7/LCC2 cells; Dr. L. Binderup (Leo Pharmaceutical Products, Ballerup, Denmark) for the gift of the vitamin D metabolite; Dr. B. Vogelstein (The John Hopkins University School of Medicine, Baltimore, MD) for providing p21 cDNA; Dr. O. Myklebost for providing the cDNAs for p27, p15, and p16 and Dr. B. Smith-Sørensen for providing p53 cDNA (both at the Norwegian Radium Hospital, Oslo, Norway); Dr. P. Meltzer (NIH, Bethesda, MD) for providing cdk4 cDNA; Dr. D. Beach (Howard Hughes Medical Institute, Cold Spring Harbor, NY) for providing cyclin D1 and cdk2 cDNAs; and Dr. P. Devilee (Medical Genetics Center South-West Netherlands, Leiden, the Netherlands) for providing BRCA-1 cDNA.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by The Norwegian Cancer Society Grant A98133 and a generous donation from a patient of A. H. R. at the Department of Oncology, The Norwegian Radium Hospital. Å. B., G. M. M., and K. B. G. are research fellows of The Norwegian Cancer Society. Back

2 To whom requests for reprints should be addressed, at Department of Tumor Biology, The Norwegian Radium Hospital, Montebello, 0310 Oslo, Norway. Phone: 47-2293-5937; Fax: 47-2252-2421; E-mail: a.h.ree{at}dnr.uio.no Back

3 The abbreviations used are: 1,25(OH)2D3, 1,25-dihydroxyvitamin D3; cdk, cyclin-dependent kinase; pRB, retinoblastoma protein; Dex, dexamethasone; E2, estradiol; RA, retinoic acid; VDR, vitamin D receptor; TBS-T, Tris-buffered saline with 0.1% Tween 20. Back

Received 2/14/00. Accepted 8/ 1/00.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Woodhouse E. C., Chuaqui R. F., Liotta L. A. General mechanisms of metastasis. Cancer (Phila.), 80: 1529-1537, 1997.[Medline]
  2. Uhr J. W., Scheuermann R. H., Street N. E., Vitetta E. S. Cancer dormancy: opportunities for new therapeutic approaches. Nat. Med., 3: 505-509, 1997.[Medline]
  3. Luzzi K. J., MacDonald I. C., Schmidt E. E., Kerkvliet N., Morris V. L., Chambers A. F., Groom A. C. Multistep nature of metastatic inefficiency. Dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am. J. Pathol., 153: 865-873, 1998.[Abstract/Free Full Text]
  4. Ree A. H., Tvermyr M., Engebraaten O., Rooman M., Røsok Ø.,, Hovig E., Meza-Zepeda, L. A., Bruland Ø. S.,, Fodstad Ø . Expression of a novel factor in human breast cancer cells with metastatic potential. Cancer Res., 59: 4675-4680, 1999.[Abstract/Free Full Text]
  5. Vink-van Wijngaarden, T., Pols H. A. P., Buurman C. J., van den Bemd, G. J. C. M., Dorssers L. C. J., Birkenhäger J. C., van Leeuwen, J. P. T. M. Inhibition of breast cancer growth by combined treatment with vitamin D3 analogues and tamoxifen. Cancer Res., 54: 5711-5717, 1994.[Abstract/Free Full Text]
  6. Elstner E., Linker-Israeli M., Said J., Umiel T., de Vos S., Shintaku I. P., Heber D., Binderup L., Uskokovic M., Koeffler H. P. 20-epi-Vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res., 55: 2822-2830, 1995.[Abstract/Free Full Text]
  7. Mørk Hansen, C., Danielsson C., Carlberg C. The potent anti-proliferative effect of 20-epi analogues of 1,25 dihydroxyvitamin D3 in human breast-cancer MCF-7 cells is related to promoter selectivity. Int. J. Cancer, 67: 739-742, 1996.[Medline]
  8. Bower M., Colston K. W., Stein R. C., Hedley A., Gazet J. C., Ford H. T., Coombes R. C. Topical calcipotriol treatment in advanced breast cancer. Lancet, 337: 701-702, 1991.[Medline]
  9. Mørk Hansen, C., Hamberg K. J., Binderup E., Binderup L. Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation. Curr. Pharm. Des., 6: 881-906, 2000.
  10. Garland F. C., Garland C. F., Gorham E. D., Young J. F. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev. Med., 19: 614-622, 1990.[Medline]
  11. Ainsleigh H. G. Beneficial effects of sun exposure on cancer mortality. Prev. Med., 22: 132-140, 1993.[Medline]
  12. Thompson E. W., Brünner N., Torri J., Johnson M. D., Boulay V., Wright A., Lippman M. E., Steeg P. S., Clarke R. The invasive and metastatic properties of hormone-independent but hormone-responsive variants of MCF-7 human breast cancer cells. Clin. Exp. Metastasis, 11: 15-26, 1993.[Medline]
  13. Brünner N., Frandsen T. L., Holst-Hansen C., Bei M., Thompson E. W., Wakeling A. E., Lippman M. E., Clarke R. MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res., 53: 3229-3232, 1993.[Abstract/Free Full Text]
  14. Clarke R., Brünner N., Thompson E. W., Glanz P., Katz D., Dickson R. B., Lippman M. E. The inter-relationships between ovarian-independent growth, tumorigenicity, invasiveness and antioestrogen resistance in the malignant progression of human breast cancer. J. Endocrinol., 122: 331-340, 1989.[Abstract/Free Full Text]
  15. Planas-Silva M. D., Weinberg R. A. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol. Cell. Biol., 17: 4059-4069, 1997.[Abstract]
  16. Liu M., Lee M. H., Cohen M., Bommakanti M., Freedman L. P. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev., 10: 142-153, 1996.[Abstract/Free Full Text]
  17. Sherr C. J. Cancer cell cycles. Science (Washington DC), 274: 1672-1677, 1996.[Abstract/Free Full Text]
  18. Verlinden L., Verstuyf A., Convents R., Marcelis S., Van Camp M., Bouillon R. Action of 1,25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol. Cell. Endocrinol., 142: 57-65, 1998.[Medline]
  19. Somasundaram K., Zhang H., Zeng Y. X., Houvras Y., Peng Y., Zhang H., Wu G. S., Licht J. D., Weber B. L., El-Deiry W. S. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CIP1. Nature (Lond.), 389: 187-190, 1997.[Medline]
  20. Blutt S. E., Allegretto E. A., Pike J. W., Weigel N. L. 1,25-Dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology, 138: 1491-1497, 1997.[Abstract/Free Full Text]
  21. Getzenberg R. H., Light B. W., Lapco P. E., Konety B. R., Nangia A. K., Acierno J. S., Dhir R., Shurin Z., Day R. S., Trump D. L., Johnson C. S. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology, 50: 999-1006, 1997.[Medline]
  22. Kawa S., Nikaido T., Aoki Y., Zhai Y., Kumagai T., Furihata K., Fujii S., Kiyosawa K. Vitamin D analogues up-regulate p21 and p27 during growth inhibition of pancreatic cancer cell lines. Br. J. Cancer, 76: 884-889, 1997.[Medline]
  23. Colston K. W., James S. Y., Ofori-Kuragu E. A., Binderup L., Grant A. G. Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro. Br. J. Cancer, 76: 1017-1020, 1997.[Medline]
  24. Wang Q. M., Jones J. B., Studzinski G. P. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res., 56: 264-267, 1996.[Abstract/Free Full Text]
  25. Carlberg C., Bendik I., Wyss A., Meier E., Sturzenbecker L. J., Grippo J. F., Hunziker W. Two nuclear signalling pathways for vitamin D. Nature (Lond.), 361: 657-660, 1993.[Medline]
  26. Mallo G. V., Fiedler F., Calvo E. L., Oritz E. M., Vasseur S., Keim V., Morriset J., Iovanna J. L. Cloning and expression of the rat p8 cDNA, a new gene activated in pancreas during the acute phase of pancreatitis, pancreatic development, and regeneration, and which promotes cellular growth. J. Biol. Chem., 272: 32360-32369, 1997.[Abstract/Free Full Text]
  27. Simboli-Campbell M., Narvaez C. J., Tenniswood M., Welsh J. 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J. Steroid Biochem. Mol. Biol., 58: 367-376, 1996.[Medline]
  28. James S. Y., Mercer E., Brady M., Binderup L., Colston K. W. EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro. Br. J. Pharmacol., 125: 953-962, 1998.[Medline]
  29. Welsh J., Van Weelden K., Flanagan L., Byrne I., Nolan E., Narvaez C. J. The role of vitamin D3 and antiestrogens in modulating apoptosis of breast cancer cells and tumors. Subcell. Biochem., 30: 245-270, 1998.[Medline]
  30. Mathiasen I. S., Lademann U., Jäättalä M. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res., 59: 4848-4856, 1999.[Abstract/Free Full Text]
  31. Vasseur S., Mallo G. V., Fiedler F., Bödeker H., Cánepa E., Moreno S., Iovanna J. L. Cloning and expression of the human p8, a nuclear protein with mitogenic activity. Eur. J. Biochem., 259: 670-675, 1999.[Medline]
  32. Holmgren L., O’Reilly M. S., Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med., 1: 149-153, 1995.[Medline]
  33. Ree A. H., Pacheco M. M., Tvermyr M., Fodstad Ø.,, Brentani M. M. Expression of a novel factor, com1, in early tumor progression of breast cancer. Clin. Cancer Res., 6: 1778-1783, 2000.[Abstract/Free Full Text]
  34. Muleris M., Almeida A., Gerbault-Seureau M., Malfoy B., Dutrillaux B. Detection of DNA amplification in 17 primary breast carcinomas with homogeneously staining regions by a modified comparative genomic hybridization technique. Genes Chromosomes Cancer, 10: 160-170, 1994.[Medline]
  35. Courjal F., Theillet C. Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification. Cancer Res., 57: 4368-4377, 1997.[Abstract/Free Full Text]
  36. Tirkkonen M., Tanner M., Karhu R., Kallioniemi A., Isola J., Kallioniemi O. P. Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer, 21: 177-184, 1998.[Medline]



This article has been cited by other articles:


Home page
 Mol. Cell. Biol.Home page
M. Ishida, M. Miyamoto, S. Naitoh, D. Tatsuda, T. Hasegawa, T. Nemoto, H. Yokozeki, K. Nishioka, A. Matsukage, M. Ohki, et al.
The SYT-SSX Fusion Protein Down-Regulates the Cell Proliferation Regulator COM1 in t(x;18) Synovial Sarcoma
Mol. Cell. Biol., February 15, 2007; 27(4): 1348 - 1355.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
G. Path, A. Opel, M. Gehlen, V. Rothhammer, X. Niu, C. Limbert, L. Romfeld, S. Hugl, A. Knoll, M. D. Brendel, et al.
Glucose-dependent expansion of pancreatic beta-cells by the protein p8 in vitro and in vivo
Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1168 - E1176.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Vasseur, E. Folch-Puy, V. Hlouschek, S. Garcia, F. Fiedler, M. M. Lerch, J. C. Dagorn, D. Closa, and J. L. Iovanna
p8 Improves Pancreatic Response to Acute Pancreatitis by Enhancing the Expression of the Anti-inflammatory Protein Pancreatitis-associated Protein I
J. Biol. Chem., February 20, 2004; 279(8): 7199 - 7207.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
G. Path, A. Opel, A. Knoll, and J. Seufert
Nuclear Protein p8 Is Associated With Glucose-Induced Pancreatic {beta}-Cell Growth
Diabetes, February 1, 2004; 53(90001): S82 - 85.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
J. S. Coker and E. Davies
Correspondence re: A. H. Ree et al., Expression of a Novel Factor in Human Breast Cancer Cells with Metastatic Potential. Cancer Res., 59: 4675-4680, 1999
Cancer Res., July 15, 2002; 62(14): 4164 - 4165.
[Full Text] [PDF]

Home page
 FASEB J.Home page
F. TOSETTI, N. FERRARI, S. DE FLORA, and A. ALBINI
Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents
FASEB J, January 1, 2002; 16(1): 2 - 14.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bratland, A.
Right arrow Articles by Ree, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bratland, A.
Right arrow Articles by Ree, A. H.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online